Method to detect bone and other connective tissue disorders in humans and animals

• US 6,121,002 A
• Filed: 06/06/1995
• Issued: 09/19/2000
• Est. Priority Date: 12/26/1990
• Status: Expired due to Term

• Current Assignee: The Rowett Research Institute (University of Aberdeen)
• Original Assignee: The Rowett Research Institute (University of Aberdeen)
• Inventors: Robins, Simon Peter
• Primary Examiner(s): STUCKER, JEFFREY J
• Application Number:
  US08/486,276
• Time in Patent Office: 1,932 Days
• Field of Search: 435/7.1, 435/7.9, 435/7.92, 435/7.94, 435/70.21, 435/240.26, 435/240.27, 435/810, 435/975, 436/512, 436/518, 436/530, 436/531, 436/548, 436/86, 436/87, 436/161, 530/387.1, 530/387.9, 530/388.1, 530/389.9, 530/391.1, 530/391.5, 530/391.7
• US Class Current: 435/7.1
• CPC Class Codes: G01N 2800/102 Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
• CPC Class Codes: G01N 2800/108 Osteoporosis
• CPC Class Codes: G01N 33/5308 for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites

Abstract

The invention is directed to methods to assess connective tissue, especially bone, metabolism in disease or to monitor therapy, which method comprises assessing the levels of native free collagen-derived crosslinks in biological fluids, especially urine. The method can be enhanced by concomitantly determining the levels of an indicator of bone formation in biological fluids of the same individual and assessing the differences between the degradation marker and the formation indicator. Antibodies which are specifically immunoreactive with forms of crosslinks which occur free in biological fluids are also disclosed.

Claims

1. A method to diagnose the presence of a disorder associated with connective tissue metabolism abnormalities, which method comprises

comparing the level of native peptide-free crosslinks derived from collagen in a non-hydrolyzed biological fluid of a human subject with the level of said crosslinks in normal subjects so as to diagnose a subject having an enhanced level of said crosslinks as showing the presence of said disorder,

wherein said crosslinks are selected from native non-glycosylated peptide-free pyridinoline (N-Pyd), native peptide-free deoxypyridinoline (N-Dpd), or a combination thereof.

2. The method of claim 1 which further includes determining the level of an indicator of bone formation in said biological fluid, determining the difference between the level of said selected native free crosslinks and the level of said indicator, and comparing this difference with the corresponding difference in normal subjects so as to diagnose a subject having an increase in said difference as showing the presence of said disorder.

3. The method of claim 1 wherein said biological fluid is serum or urine.

4. The method of claim 2 wherein said biological fluid is serum or urine.

5. The method of claim 1 wherein said selected crosslinks are determined as the total of N-Pyd, N-Dpd, and native glycosylated peptide-free Pyd.

6. The method of claim 2 wherein said selected crosslinks are determined as the total of N-Pyd, N-Dpd, and native glycosylated peptide-free Pyd.

7. The method of claim 1 wherein said selected crosslinks are determined as N-Pyd, N-Dpd, or the sum thereof.

8. The method of claim 2 wherein said selected crosslinks are determined as N-Pyd, N-Dpd, or the sum thereof.

9. The method of claim 1 wherein said determination of said selected crosslinks utilizes an immunoassay comprising the step of contacting the biological fluid or a fraction thereof with a composition containing an antibody or immunologically reactive fragment thereof which composition is specifically immunoreactive with said selected crosslinks.

10. The method of claim 2 wherein said determination of said selected crosslinks utilizes an immunoassay comprising the step of contacting the biological fluid or a fraction thereof with a composition containing an antibody or immunologically reactive fragment thereof which composition is specifically immunoreactive with said selected crosslinks.

11. The method of claim 9 wherein said selected crosslinks are determined as the total of N-Pyd, N-Dpd, and native glycosylated peptide-free Pyd.

12. The method of claim 10 wherein said selected crosslinks are determined as the total of N-Pyd, N-Dpd, and native glycosylated peptide-free Pyd.

13. The method of claim 9 wherein said selected crosslinks are determined as N-Pyd, N-Dpd, or the sum thereof.

14. The method of claim 10 wherein said selected crosslinks are determined as N-Pyd, N-Dpd, or the sum thereof.

15. A method to monitor the effects of a therapy protocol in a human subject, which method comprises

comparing the level of native peptide-free crosslinks derived from collagen in a non-hydrolyzed biological fluid of the subject at various time points within and/or after the protocol with the level of said crosslinks prior to administration of the protocol so as to evaluate a subject having a decreased level of said crosslinks as showing the effectiveness of said protocol wherein said crosslinks are selected from native non-glycosylated peptide-free pyridinoline (N-Pyd), native peptide-free deoxypyridinoline (N-Dpd), or a combination thereof.

16. The method of claim 15 wherein said biological fluid is serum or urine.

17. The method of claim 15 wherein said native peptide-free crosslinks are determined as the total of N-Pyd and N-Dpd.

18. The method of claim 15 wherein said free crosslinks are determined as N-Pyd and N-Dpd.

19. A method to determine the breakdown of connective tissue, which method comprises determining the ratio of Pyd/Dpd in a non-hydrolyzed biological fluid of a subject and comparing said ratio to that in normal controls, wherein an increase in said ratio in said subject over normal controls indicates connective tissue breakdown in said subject.